MCID: BRN015
MIFTS: 42

Bronchiolo-Alveolar Adenocarcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Bronchiolo-Alveolar Adenocarcinoma

MalaCards integrated aliases for Bronchiolo-Alveolar Adenocarcinoma:

Name: Bronchiolo-Alveolar Adenocarcinoma 12 15
Minimally Invasive Lung Adenocarcinoma 12
Adenocarcinoma, Bronchiolo-Alveolar 44
Bronchioloalveolar Adenocarcinoma 73
Bronchioalveolar Lung Carcinoma 12
Bronchioloalveolar Carcinoma 12
Carcinoma Bronchioloalveolar 55

Classifications:



External Ids:

Disease Ontology 12 DOID:4926
MeSH 44 D002282
NCIt 50 C2923
SNOMED-CT 68 36310008
UMLS 73 C0007120

Summaries for Bronchiolo-Alveolar Adenocarcinoma

Disease Ontology : 12 A lung adenocarcinoma characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension.

MalaCards based summary : Bronchiolo-Alveolar Adenocarcinoma, also known as minimally invasive lung adenocarcinoma, is related to mucinous bronchioloalveolar adenocarcinoma and adenocarcinoma, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Bronchiolo-Alveolar Adenocarcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Glioma and O-linked glycosylation. The drugs Gefitinib and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lung, colon and ovary, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Related Diseases for Bronchiolo-Alveolar Adenocarcinoma

Diseases related to Bronchiolo-Alveolar Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)
# Related Disease Score Top Affiliating Genes
1 mucinous bronchioloalveolar adenocarcinoma 32.1 CDX2 KRT20 KRT7 NKX2-1
2 adenocarcinoma 30.6 CDH1 EGFR KRAS MUC4
3 sclerosing hemangioma 30.5 KRT7 NKX2-1
4 solid adenocarcinoma with mucin production 30.0 KRT7 MUC6 NKX2-1
5 papillary adenocarcinoma 29.9 CDH1 KRT7 MUC2 NKX2-1
6 adenocarcinoma in situ 29.8 CDX2 KRAS KRT20 KRT7
7 mucinous adenocarcinoma 29.1 CDX2 EGFR KRAS KRT20 KRT7 MUC2
8 lung cancer 29.1 CDH1 EGFR FHIT KRAS KRT20 KRT7
9 lung cancer susceptibility 3 29.0 CDH1 CDX2 EGFR FHIT KRAS KRT20
10 mixed mucinous and nonmucinous bronchioloalveolar adenocarcinoma 11.5
11 nonmucinous bronchioloalveolar adenocarcinoma 11.5
12 in situ pulmonary adenocarcinoma 11.2
13 acneiform dermatitis 10.3 EGFR KRAS
14 respiratory system benign neoplasm 10.3 KRAS NKX2-1
15 basaloid squamous cell carcinoma 10.3 EGFR KRT7
16 lung adenoid cystic carcinoma 10.3 KRAS NKX2-1
17 intestinal perforation 10.3 KRT7 NKX2-1
18 atypical choroid plexus papilloma 10.3 KRT7 NKX2-1
19 pulmonary sclerosing hemangioma 10.3 KRT7 NKX2-1
20 adenomatoid tumor 10.3 KRT7 NKX2-1
21 rete testis adenocarcinoma 10.3 KRT20 NKX2-1
22 rete testis neoplasm 10.3 KRT20 NKX2-1
23 paget disease, extramammary 10.2 KRT20 KRT7
24 immune system organ benign neoplasm 10.2 KRT20 KRT7
25 bladder lymphoma 10.2 KRT20 KRT7
26 eccrine sweat gland neoplasm 10.2 KRT20 KRT7
27 thymus lipoma 10.2 KRT20 KRT7
28 dermoid cyst 10.2 KRT20 KRT7
29 hepatoid adenocarcinoma 10.2 CDX2 EGFR
30 medulloepithelioma 10.2 KRT20 KRT7
31 renal pelvis carcinoma 10.2 KRT20 KRT7
32 glycogen-rich clear cell breast carcinoma 10.2 KRT20 KRT7
33 cystadenofibroma 10.2 KRT20 KRT7
34 meibomian cyst 10.2 KRT20 KRT7
35 benign breast adenomyoepithelioma 10.2 EGFR KRT7
36 lipid-rich carcinoma 10.2 CDH1 EGFR
37 inflammatory breast carcinoma 10.2 CDH1 EGFR
38 nasal cavity cancer 10.2 CDX2 KRT7
39 mucinous ovarian cystadenoma 10.2 CDX2 KRT7
40 sarcomatoid mesothelioma 10.2 MUC4 NKX2-1
41 paronychia 10.2 EGFR KRAS
42 breast myoepithelial neoplasm 10.2 CDH1 KRT7
43 breast secretory carcinoma 10.2 KRT7 MUC4
44 cystic basal cell carcinoma 10.2 KRT20 KRT7
45 ovarian germ cell teratoma 10.2 KRT7 NKX2-1
46 pneumonia 10.2
47 seminal vesicle adenocarcinoma 10.2 KRT20 KRT7
48 transverse colon cancer 10.2 KRT20 KRT7
49 oncocytic breast carcinoma 10.2 EGFR KRT7
50 malignant syringoma 10.2 KRT20 KRT7

Graphical network of the top 20 diseases related to Bronchiolo-Alveolar Adenocarcinoma:



Diseases related to Bronchiolo-Alveolar Adenocarcinoma

Symptoms & Phenotypes for Bronchiolo-Alveolar Adenocarcinoma

UMLS symptoms related to Bronchiolo-Alveolar Adenocarcinoma:


fever, dyspnea, hemoptysis, coughing

MGI Mouse Phenotypes related to Bronchiolo-Alveolar Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 CDH1 CDX2 EGFR FHIT KRAS MUC2
2 homeostasis/metabolism MP:0005376 9.61 CDH1 CDX2 EGFR FHIT HYAL2 KRAS
3 neoplasm MP:0002006 9.17 CDH1 CDX2 EGFR FHIT KRAS MUC2

Drugs & Therapeutics for Bronchiolo-Alveolar Adenocarcinoma

Drugs for Bronchiolo-Alveolar Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
2
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
3
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 38904 498142
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
5
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
7
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
8
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
9
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
10
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
11
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
12
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
13
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
15 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
16
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
17 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
18 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1
19 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
20 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1
21 Anti-Infective Agents Phase 3,Phase 2,Phase 1
22 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
23 Antimetabolites Phase 3,Phase 2,Phase 1
24 Antiviral Agents Phase 3,Phase 2,Phase 1
25 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
26 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 3,Phase 1
27 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
28 Antibodies Phase 2, Phase 3,Phase 1
29 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
30 Immunoglobulins Phase 2, Phase 3,Phase 1
31 Etoposide phosphate Phase 3,Phase 2,Phase 1
32 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
33 Mitogens Phase 3,Phase 2
34 Hematinics Phase 3,Phase 2
35 Epoetin alfa Phase 3 113427-24-0
36 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
37 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
38 Vitamin B Complex Phase 3,Phase 2,Phase 1
39 Folate Phase 3,Phase 2,Phase 1
40 Vitamin B9 Phase 3,Phase 2,Phase 1
41 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
42
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
43
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
44
Promethazine Approved, Investigational Phase 2 60-87-7 4927
45
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
46
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
47
Vinblastine Approved Phase 2,Phase 1 865-21-4 241903 13342
48
Topotecan Approved, Investigational Phase 2,Phase 1 123948-87-8, 119413-54-6 60700
49
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
50
Lomustine Approved, Investigational Phase 2 13010-47-4 3950

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
2 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
3 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
4 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
5 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
6 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
7 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
8 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
9 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
10 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
11 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
12 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
13 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
14 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
15 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
16 Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
17 Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
18 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
19 Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma Completed NCT00430261 Phase 2 sunitinib
20 Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00029003 Phase 2 gefitinib
21 Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer Completed NCT00118144 Phase 2 bortezomib
22 Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer Completed NCT00103207 Phase 2
23 Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma Completed NCT00384826 Phase 2 erlotinib;paclitaxel + carboplatine
24 Paclitaxel in Treating Patients With Lung Cancer Completed NCT00002972 Phase 2 paclitaxel
25 S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00002969 Phase 2 paclitaxel
26 Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00416650 Phase 2 erlotinib hydrochloride
27 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
28 Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). Completed NCT01116219 Phase 2 bevacizumab, pemetrexed, cisplatin
29 Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00411047 Phase 2 gefitinib
30 Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer Completed NCT00103116 Phase 2
31 Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00003666 Phase 2 6-hydroxymethylacylfulvene
32 Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function Completed NCT00002624 Phase 2
33 Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
34 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
35 Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
36 Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers Completed NCT01344824 Phase 2 carboplatin;erlotinib hydrochloride;pemetrexed disodium
37 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00553462 Phase 2 carboplatin;erlotinib hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
38 Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00425646 Phase 2 imatinib mesylate
39 Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed NCT00970684 Phase 2 docetaxel;gemcitabine hydrochloride
40 Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00309998 Phase 2 vinorelbine tartrate
41 Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy Completed NCT00365547 Phase 2 topotecan hydrochloride
42 Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC Completed NCT00354549 Phase 2 bevacizumab + erlotinib hydrochloride;gemcitabine hydrochloride + cisplatin or carboplatin
43 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00117962 Phase 2 carboplatin;pemetrexed disodium
44 Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer Completed NCT00087438 Phase 2
45 Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00081302 Phase 2 carboplatin;paclitaxel
46 Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer Completed NCT00033553 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
47 Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
48 Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00278460 Phase 2 docetaxel;gemcitabine hydrochloride
49 Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT01302808 Phase 1, Phase 2 erlotinib hydrochloride;romidepsin
50 Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed NCT00346320 Phase 2

Search NIH Clinical Center for Bronchiolo-Alveolar Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, bronchiolo-alveolar

Genetic Tests for Bronchiolo-Alveolar Adenocarcinoma

Anatomical Context for Bronchiolo-Alveolar Adenocarcinoma

MalaCards organs/tissues related to Bronchiolo-Alveolar Adenocarcinoma:

41
Lung, Colon, Ovary, Pancreas, Thymus, Appendix

Publications for Bronchiolo-Alveolar Adenocarcinoma

Articles related to Bronchiolo-Alveolar Adenocarcinoma:

# Title Authors Year
1
CT-texture analysis of subsolid nodules for differentiating invasive from in-situ and minimally invasive lung adenocarcinoma subtypes. ( 29477490 )
2018
2
Primary bronchiolo-alveolar adenocarcinoma in a dromedary camel (Camelus dromedarius). ( 9549871 )
1998
3
Primary bronchiolo-alveolar adenocarcinoma in a bull. ( 8677609 )
1996
4
Bronchiolo-alveolar adenocarcinoma in a horse. ( 2562160 )
1989
5
Bronchiolo-alveolar adenocarcinoma with multiple cysts. ( 6287799 )
1982

Variations for Bronchiolo-Alveolar Adenocarcinoma

Cosmic variations for Bronchiolo-Alveolar Adenocarcinoma:

9 (show top 50) (show all 13387)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6926570 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 12
2 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 12
3 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 12
4 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 12
5 COSM6145051 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.562G>T p.A188S 16:72959584-72959584 12
6 COSM6978013 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1855C>G p.H619D 16:72958291-72958291 12
7 COSM6956103 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2437A>T p.T813S 16:72957709-72957709 12
8 COSM6826441 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 12
9 COSM6975161 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5985C>G p.I1995M 16:72796697-72796697 12
10 COSM6932802 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2842G>T p.A948S 16:72950843-72950843 12
11 COSM6954614 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 12
12 COSM6967535 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3070G>T p.A1024S 16:72950615-72950615 12
13 COSM6933870 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3763C>T p.P1255S 16:72811678-72811678 12
14 COSM6926444 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10766C>G p.S3589C 16:72787510-72787510 12
15 COSM6933260 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 12
16 COSM6950021 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2135G>T p.R712L 16:72958011-72958011 12
17 COSM6965155 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 12
18 COSM6972801 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 12
19 COSM6982281 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 12
20 COSM6937412 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1775A>C p.D592A 16:72958371-72958371 12
21 COSM6969901 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 12
22 COSM6964729 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5670G>C p.Q1890H 16:72797012-72797012 12
23 COSM6931279 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1530G>T p.E510D 16:72958616-72958616 12
24 COSM6935718 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 12
25 COSM6929247 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8677G>C p.G2893R 16:72794005-72794005 12
26 COSM6945078 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 12
27 COSM6935881 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1352G>T p.C451F 16:72958794-72958794 12
28 COSM6940635 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 12
29 COSM6969446 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 12
30 COSM6968693 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 12
31 COSM6926443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10885C>G p.P3629A 16:72787391-72787391 12
32 COSM6962405 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 12
33 COSM6970007 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 12
34 COSM6977567 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 12
35 COSM5796563 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.445C>T p.Q149* 16:72959701-72959701 12
36 COSM6966467 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5788T>C p.S1930P 16:72796894-72796894 12
37 COSM6970295 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 12
38 COSM6968715 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 12
39 COSM6982440 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 12
40 COSM6983995 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7133C>G p.T2378S 16:72795549-72795549 12
41 COSM6962938 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4181C>A p.S1394* 16:72798501-72798501 12
42 COSM6937443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 12
43 COSM6953061 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10994A>T p.D3665V 16:72787282-72787282 12
44 COSM6953714 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3431G>T p.C1144F 16:72889748-72889748 12
45 COSM6969956 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.527G>T p.G176V 16:72959619-72959619 12
46 COSM4062722 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2486T>C p.M829T 16:72957660-72957660 12
47 COSM6939807 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1408G>T p.E470* 16:72958738-72958738 12
48 COSM48850 ZAP70 lung,NS,carcinoma,adenocarcinoma c.1484C>T p.A495V 2:97737758-97737758 12
49 COSM95551 YWHAE lung,NS,carcinoma,adenocarcinoma c.146A>G p.Y49C 17:1364977-1364977 12
50 COSM48846 YES1 lung,NS,carcinoma,adenocarcinoma c.473G>T p.W158L 18:746049-746049 12

Expression for Bronchiolo-Alveolar Adenocarcinoma

Search GEO for disease gene expression data for Bronchiolo-Alveolar Adenocarcinoma.

Pathways for Bronchiolo-Alveolar Adenocarcinoma

Pathways related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 CDH1 EGFR FHIT KRAS
2
Show member pathways
11.96 MUC2 MUC4 MUC6
3 11.87 CDH1 EGFR KRAS
4
Show member pathways
11.87 KRAS MUC2 MUC4 MUC6
5 11.8 CDH1 EGFR KRAS
6
Show member pathways
11.74 MUC2 MUC4 MUC6
7
Show member pathways
11.69 CDH1 CDX2 EGFR KRAS MUC2
8
Show member pathways
11.54 MUC2 MUC4 MUC6
9 11.3 CDH1 EGFR KRAS
10 11.04 CDH1 EGFR
11 11.01 EGFR KRAS
12 10.94 EGFR KRAS
13
Show member pathways
10.91 EGFR KRAS
14 10.91 CDH1 CDX2 NKX2-1
15 10.65 CDH1 EGFR

GO Terms for Bronchiolo-Alveolar Adenocarcinoma

Cellular components related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC2 MUC4 MUC6

Biological processes related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pituitary gland development GO:0021983 9.37 CDH1 NKX2-1
2 O-glycan processing GO:0016266 9.33 MUC2 MUC4 MUC6
3 epithelial tube branching involved in lung morphogenesis GO:0060441 9.32 KRAS NKX2-1
4 cerebral cortex cell migration GO:0021795 9.26 EGFR NKX2-1
5 maintenance of gastrointestinal epithelium GO:0030277 9.13 MUC2 MUC4 MUC6
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 8.92 KRAS MUC2 MUC4 MUC6

Sources for Bronchiolo-Alveolar Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....